ReviewClinical & developmental immunology2009
Cancer vaccine by fusions of dendritic and cancer cells.
Review in Clinical & developmental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- How Do Cancer Cells Fuse and Why?Advances in experimental medicine and biology · 2026Review
- Targets and Strategies for Cancer Immunoprevention.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting.Cancers · 2020Review
- Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.International journal of molecular sciences · 2016Review
- Functional characterization of biodegradable nanoparticles as antigen delivery system.Journal of experimental & clinical cancer research : CR · 2015Article
- Article
- Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions.Oncoimmunology · 2013Review
- Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation.Oncoimmunology · 2013Article
- The combination of TLR2 and TLR4 agonists promotes the immunogenicity of dendritic cell/cancer cell fusions.Oncoimmunology · 2013Article
- Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.Journal of translational medicine · 2013Article
- Particle platforms for cancer immunotherapy.International journal of nanomedicine · 2013Review
- Potential targets for pancreatic cancer immunotherapeutics.Immunotherapy · 2011Review
- Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Journal of biomedicine & biotechnology · 2011Review
- Translating tumor antigens into cancer vaccines.Clinical and vaccine immunology : CVI · 2011Review
- Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.Journal of immunology (Baltimore, Md. : 1950) · 2010Review
- Theoretical modeling techniques and their impact on tumor immunology.Clinical & developmental immunology · 2010Review
- Regulation of tumor immunity by tumor/dendritic cell fusions.Clinical & developmental immunology · 2010Review
- Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are potent antigen-presenting cells and play a central role in the initiation and regulation of primary immune responses. Therefore, their use for the active immunotherapy against cancers has been studied with considerable interest. The fusion of DCs with whole tumor cells represents in many ways an ideal approach to deliver, process, and subsequently present a broad array of tumor-associated antigens, including those yet to be unidentified, in the context of DCs-derived costimulatory molecules. DCs/tumor fusion vaccine stimulates potent antitumor immunity in the animal tumor models. In the human studies, T cells stimulated by DC/tumor fusion cells are effective in lysis of tumor cells that are used as the fusion partner. In the clinical trials, clinical and immunological responses were observed in patients with advanced stage of malignant tumors after being vaccinated with DC/tumor fusion cells, although the antitumor effect is not as vigorous as in the animal tumor models. This review summarizes recent advances in concepts and techniques that are providing new impulses to DCs/tumor fusions-based cancer vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.